Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Contribute

España

India

Italia

대한민국

日本

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Research

My Stocks

Tools

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Trade Ideas

Unusual Options Activity

Heatmaps

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Calculators

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Timothy Chiang

TiGenix Downgraded As Shares Soar Above BTIG's Price Target

Risks For Teva Remain As CEO Search Continues

Competition For Mylan's Generic Concerta Is Limited

Risks For Teva Remain As CEO Search Continues

Competition For Mylan's Generic Concerta Is Limited

Has Synergy Pharmaceuticals Become A Takeout Candidate Following 2 Recent Phase 3 Trial Successes?

Shire Could Have A Game Changer In The Making

Has Synergy Pharmaceuticals Become A Takeout Candidate Following 2 Recent Phase 3 Trial Successes?

Shire Could Have A Game Changer In The Making

Synergy Reports Positive Phase 3-Trial 1 Data

Key Exec Announcing His Retirement From Teva 'Creates More Uncertainties'

Timothy Chiang Recent News

Synergy's Incoming FDA Catalyst

Teva Pharmaceuticals Hit With A Slew Of Downgrades Following Guidance Revision

Valeant Shares Surge, But BTIG Remains Cautious On Recovery

BTIG Still Buying Relypsa As May Prescription Trends Show Steady Veltassa Increases

As Veltassa Continues To Grow, BTIG Still Buying Relypsa

BTIG Cuts Veltassa Estimates, Relypsa's Price Target To $35

Perrigo's CEO Departure Leaves More Questions Than Answers; BTIG Downgrades Stock

Shire Just Took Another Step Forward With Its ADHD Drug

BTIG: Buy Teva On Weakness, U.S. Lawmakers Have Little Appetite For Direct Government Negotiation Of Drug Prices

BTIG Recommends 'Beaten Down' Drug Manufacturers Like Teva

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap